Our Vision
As a biopharma founded in 2022 by Boehringer Ingelheim, Evotec and bioMérieux, AUROBAC THERAPEUTICS ambitions to become a leader in the fight against bacterial infections, Antimicrobial Resistance (AMR) and their consequences in acute hospital settings.
AUROBAC THERAPEUTICS’ R&D strategy encompasses patient- and pathogen-targeted programs designed to tackle both the causes and consequences of serious bacterial infections and AMR, including hospital-acquired and ventilator-associated bacterial pneumonia and sepsis. Central to this approach is the adoption of innovative diagnostic strategies developed in partnership with bioMérieux, aimed at facilitating patient stratification and optimizing treatment outcomes.
Ultimately, we want to be able to demonstrate the clinical and medico-economic value of all the products we develop and to define a new adapted and sustainable economic model.
“The rise of Antimicrobial Resistance worldwide jeopardizes the prevention and treatment of life-threatening resistant bacterial infections, which are already killing 1.3 million people per year. AUROBAC has the ambition to become a leader in the fight against bacterial infections, AMR and their consequences in acute hospital settings with a unique combination of the best capabilities of the three founding companies, Boehringer Ingelheim, bioMérieux and Evotec.
Our diagnostic-driven strategy and innovative pipeline underscore our dedication to developing a new generation of precision drugs and improving outcomes for patients in urgent need.”
Florence Séjourné, CEO
AUROBAC THERAPEUTICS is proud to be a member of the BEAM Alliance
AUROBAC ©2024 – Legal Notice – Privacy Statement – Photo Credits